Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CC-95775 · 1 trial · 1 indication
is defined as any toxicities occurring within the DLT assessment unless the event can clearly be determined to be unrelated to CC-95775.
dose level that could be given such that the estimated DLT probability is closest to 25%.
The dose that is higher than MTD
Number of participants with adverse event. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study
| Arm | Type | Description |
|---|---|---|
| CC-95775 | EXPERIMENTAL | Escalating dose finding part A of study and extension Part B of the study. In Part A, subjects will be treated with oral capsules of CC-95775 with a schedule of 4d on/ 24d off (Q4W) and a starting dose of 100 mg/day on a 28-day cycle. Dose increments between cohorts will not exceed 100% of the dose in previous cohort. Patients in Part B will be treated with a schedule of 4d on/24d off (Q4W) at the Maximum tolerated dose (MTD) established from Part A. |
| Name | Type | Description |
|---|---|---|
| CC-95775 | DRUG | CC-95775 |
Inclusion Criteria: Subjects must satisfy the criteria below to be enrolled in dose escalation (Part A) and in dose expansion (Part B) of this study. 1. Men and women ≥ 18 years of age, at the time of signing the ICF. 2. Subject must understand and voluntarily sign an ICF prior to any study-specif...
CC-95775 is an investigational small molecule being studied for the treatment of relapsed or refractory Non-Hodgkin Lymphoma. It is also being evaluated in advanced solid tumors. The drug is in Phase 1 clinical development and is not yet approved by the FDA.
CC-95775 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational oncology drug.
CC-95775 is in Phase 1 clinical development. A Phase 1 study has been completed to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors and relapsed or refractory Non-Hodgkin Lymphoma.
CC-95775 has one completed clinical trial, NCT04089527, which was a Phase 1 study in patients with advanced solid tumors and relapsed or refractory Non-Hodgkin Lymphoma. The trial enrolled 24 participants and was conducted in France and Spain.
CC-95775 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial focused on safety and tolerability, and further studies would be needed to establish efficacy and seek regulatory approval.